The Filing Desk

Sinovac Biotech

SVA · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

Sinovac Biotech's revenue rose 6.8% to $386 million in fiscal 2025. Its operating margin was −127.0%, up from −139.9% a year earlier. Free cash flow was −$561 million. It paid out $3.5 billion in dividends and buybacks.

SINOVAC BIOTECH LTD Latest fiscal year ended December 31, 2025 20-F filed June 5, 2026 · 0001193125-26-258534 Updated
Revenue
$386M
6.8%
Operating margin
−127.0%
12.9 pts
Net income
−$199M
$41M a year earlier
Free cash flow
−$561M
 
Return on equity
−3.1%
3.6 pts

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.

About these figures. Sinovac Biotech is a foreign company: it files an annual report on Form 20-F, prepared under US accounting standards (US GAAP), instead of a 10-K, and no quarterly reports, so this page has fiscal years only. Its shares trade in the US as American depositary shares (ADSs), and one ADS can stand for several ordinary shares, so per-share figures are per ordinary share and the page has no market value, P/E or valuation model.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2017 to 2024, earnings per share grew 16.0% a year and net income 6.7% a year, as new shares raised the share count by 26% and diluted each share's earnings. Sinovac Biotech then lost money in fiscal 2025.

Diluted earnings per share
US$ per ordinary share, fiscal years; loss years in red. One US-listed ADS can stand for several ordinary shares.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments13,41510,53211,0189,9495,971
Debt incl. finance leases1612254376495
Net debt (negative means net cash)−13,400−10,520−10,765−9,573−5,476
Net debt to EBITDA−0.8x————
Debt to equity0.0x0.0x0.0x0.1x0.1x
Interest coverage6,212.4x−402.7x−144.5x−89.7x−49.9x
Current ratio5.9x9.0x9.0x7.3x4.6x
Quick ratio5.8x8.9x8.9x7.3x4.5x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score3 of 92 of 93 of 9
Rule of 40−71.8%−65.4%−138.5%
Altman Z''12.4511.718.06
Accruals ratio−1.1%0.8%3.0%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailPassFail
Cash from operations is positivePassFailFail
Return on assets roseFailPassFail
Cash from operations exceeds net incomePassFailFail
Debt fell relative to assetsFailFailFail
Current ratio roseFailFailFail
Share count didn't riseFailFailPass
Gross margin rosePassFailPass
Revenue rose relative to assetsFailFailPass
F-score3 of 92 of 93 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Sinovac Biotech side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Sinovac BiotechFY256.8%−127.0%−145.4%——3
Arcutis BiotherapeuticsFY2591.3%−3.2%−1.7%−16.9%—4Compare
Pharming GroupFY2526.6%6.9%14.3%———Compare
ArdelyxFY2522.1%−10.1%−10.8%−36.1%—2Compare
InnovivaFY2514.7%39.8%47.6%17.9%—6Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue7217423024651119,3651,473470361386
Revenue growth7.4%140.7%31.7%7.1%107.5%3,692.5%−92.4%−68.1%−23.1%6.8%
Gross profit5015420521444318,376815323221262
Research and development1320222449153479350271216
Operating income045456921617,618−509−714−506−490
Net income−12622451108,12214−1441−199
Diluted EPS (US$)−0.010.450.340.410.97113.440.20−0.191.27−0.83
Diluted shares (millions)5757651101147272727272
Cash flow
Cash from operations−146083947915,322−798139−57−512
Capital expenditure13126111285943141569649
Free cash flow−274822835214,728−1,112−18−153−561
Dividends paid000001,8762473289473,534
Share buybacks0000000000
Acquisitions0000000010014
Stock-based compensation21431080000
Balance sheet at fiscal year end
Cash and short-term investments621141772031,17613,41510,53211,0189,9495,971
Debt incl. finance leases413376351612254376495
Total assets2112993704521,90116,75914,03013,61212,3378,542
Total liabilities82122781007813,2061,7871,9702,0442,146
Shareholders' equity1161512532947468,9958,4918,3168,2624,439
Margins and ratios
Gross margin69.1%88.4%89.2%86.8%86.8%94.9%55.3%68.8%61.1%67.9%
Operating margin0.7%26.1%19.7%27.9%42.2%91.0%−34.5%−151.9%−139.9%−127.0%
Net margin−0.8%14.8%9.5%18.3%21.6%41.9%1.0%−2.9%11.2%−51.5%
Free cash flow margin−36.7%27.4%1.0%11.6%68.9%76.0%−75.5%−3.7%−42.3%−145.4%
Rule of 40 (growth + FCF margin)−29.2%168.2%32.7%18.7%176.4%3,768.5%−167.9%−71.8%−65.4%−138.5%
Return on capital—36.3%32.3%45.5%——————
Return on equity−0.5%19.3%10.8%16.4%21.2%166.8%0.2%−0.2%0.5%−3.1%
Return on assets−0.3%10.1%6.5%10.9%9.4%87.0%0.1%−0.1%0.3%−1.9%
Net debt to EBITDA−3.9x−1.6x−3.4x−2.7x−5.2x−0.8x————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Sinovac Biotech's Form 20-F filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Sinovac Biotech.